HK1251580B - 製造膜聯蛋白v的方法 - Google Patents
製造膜聯蛋白v的方法Info
- Publication number
- HK1251580B HK1251580B HK18107461.5A HK18107461A HK1251580B HK 1251580 B HK1251580 B HK 1251580B HK 18107461 A HK18107461 A HK 18107461A HK 1251580 B HK1251580 B HK 1251580B
- Authority
- HK
- Hong Kong
- Prior art keywords
- annexin
- manufacture
- Prior art date
Links
- 102000000412 Annexin Human genes 0.000 title 1
- 108050008874 Annexin Proteins 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1516516.0A GB2542391A (en) | 2015-09-17 | 2015-09-17 | Process of manufacture |
PCT/EP2016/072066 WO2017046391A2 (en) | 2015-09-17 | 2016-09-16 | Process of manufacture |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1251580B true HK1251580B (zh) | 2019-10-18 |
Family
ID=54544424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18107461.5A HK1251580B (zh) | 2015-09-17 | 2018-06-07 | 製造膜聯蛋白v的方法 |
Country Status (11)
Country | Link |
---|---|
US (3) | US11773134B2 (zh) |
EP (3) | EP3283506B1 (zh) |
JP (4) | JP6689371B2 (zh) |
CN (3) | CN108137662B (zh) |
CA (2) | CA3036298A1 (zh) |
DK (2) | DK3453721T3 (zh) |
ES (2) | ES2920156T3 (zh) |
GB (1) | GB2542391A (zh) |
HK (1) | HK1251580B (zh) |
PL (2) | PL3283506T3 (zh) |
WO (1) | WO2017046391A2 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3495376A1 (en) * | 2017-12-05 | 2019-06-12 | ChromaCon AG | Improved chromatographic process for cell culture harvest |
EP3560945A1 (en) * | 2018-04-27 | 2019-10-30 | F. Hoffmann-La Roche AG | Methods for purification of polypeptides using polysorbates |
US20210198309A1 (en) * | 2018-08-31 | 2021-07-01 | Kaneka Corporation | Method for purifying antibody or antibody-like molecule |
CN110669141A (zh) * | 2019-09-29 | 2020-01-10 | 杭州联科生物技术股份有限公司 | 一种别藻蓝蛋白(APC)与Annexin V蛋白偶联方法 |
TW202146042A (zh) * | 2020-03-06 | 2021-12-16 | 瑞典商阿斯特捷利康公司 | 用於治療動脈和靜脈血栓形成的協同且靶向的組成物 |
CN111378005B (zh) * | 2020-04-03 | 2021-08-17 | 安徽环球基因科技有限公司 | 一种可调式纯化蛋白装置 |
WO2023104874A2 (en) * | 2021-12-08 | 2023-06-15 | Ferring B.V. | Method |
CN114539383B (zh) * | 2022-02-24 | 2024-03-26 | 南京大学 | 一种人源膜联蛋白人源膜联蛋白a5突变体二聚体的晶体结构的制备方法和应用 |
GB202207263D0 (en) * | 2022-05-18 | 2022-06-29 | Annexin Pharmaceuticals Ab | Therapeutic compositions |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0209568B1 (en) | 1985-01-10 | 1994-07-20 | Biogen, Inc. | Dna sequences, recombinant dna molecules and processes for producing human lipocortin-like polypeptides |
DE3643182A1 (de) | 1986-12-18 | 1988-06-30 | Behringwerke Ag | Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4 |
DE3939169A1 (de) | 1989-11-27 | 1991-05-29 | Behringwerke Ag | Verfahren zur reinigung von lipocortinen |
DE4003773A1 (de) * | 1990-02-08 | 1991-08-14 | Behringwerke Ag | Verfahren zur reinigung von lipocortinen |
DE4012341A1 (de) * | 1990-04-18 | 1991-10-24 | Behringwerke Ag | Monoklonale antikoerper gegen pp4, verfahren zu ihrer herstellung und ihre verwendung |
US5968477A (en) * | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
JP2000239299A (ja) | 1999-02-15 | 2000-09-05 | Snow Brand Milk Prod Co Ltd | 新規蛋白質及びその製造方法 |
US6492327B2 (en) * | 2000-12-19 | 2002-12-10 | Sulzer Biologics Inc. | Isolation of purified TGF- β1 and TGF -β2 from bone tissue |
GB0101300D0 (en) * | 2001-01-18 | 2001-02-28 | Univ Cambridge Tech | Primordial germ cell genes |
US7635680B2 (en) * | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
DE60219611T2 (de) | 2001-02-21 | 2007-12-27 | Alavita Pharmaceuticals, Inc., Mountain View | Modifizierte annexin-proteine und verhinderung und behandlung von thrombose |
US7645739B2 (en) | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
EP1389090A2 (en) * | 2001-04-26 | 2004-02-18 | Board of Regents, The University of Texas System | Diagnostic imaging compositions, their methods of synthesis and use |
US6825027B2 (en) * | 2001-12-10 | 2004-11-30 | Baxter Healthcare S.A. | Method of production of purified hepatitis a virus particles and vaccine preparation |
CH696701A5 (de) * | 2001-12-18 | 2007-10-15 | Hoffmann La Roche | Verfahren zum Testen eines Mittels auf dessen Fähigkeit, die Heparanaseaktivität zu hemmen. |
US7148049B2 (en) * | 2002-04-02 | 2006-12-12 | Roche Molecular Systems, Inc. | Thermostable or thermoactive DNA polymerase molecules with attenuated 3′-5′ exonuclease activity |
MY142798A (en) | 2003-03-04 | 2010-12-31 | Smithkline Beecham Corp | Methods for preventing glyconoylation of proteins |
CA2559167A1 (en) | 2004-03-11 | 2005-09-22 | Alavita, Inc. | Modified annexin proteins and methods for preventing thrombosis |
JP2007532617A (ja) * | 2004-04-15 | 2007-11-15 | アテラ バイオテクノロジーズ エービー | アテローム血栓症およびプラーク破壊を予防するためのアネキシンv |
EP1769003A1 (en) * | 2004-07-06 | 2007-04-04 | Bioren, Inc. | HIGH AFFINITY ANTI-TNF-alpha ANTIBODIES AND METHOD |
US7511016B2 (en) * | 2004-07-07 | 2009-03-31 | Mosamedix B.V. | Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
WO2006081320A2 (en) * | 2005-01-27 | 2006-08-03 | Human Genome Sciences, Inc. | Pharmaceutical formulation |
PL2234631T3 (pl) * | 2007-12-18 | 2013-03-29 | Athera Biotechnologies Ab | Związki i metody stosowane w terapii choroby naczyniowej |
GB0905348D0 (en) | 2009-03-27 | 2009-05-13 | Ucl Business Plc | Carrier |
ES2630013T3 (es) * | 2008-02-22 | 2017-08-17 | Annexin Pharmaceuticals Ab | Compuestos y procedimientos para la prevención o tratamiento de reestenosis |
ITCZ20080004A1 (it) * | 2008-02-26 | 2009-08-27 | Univ Bari | Anticorpo monospecifico e metodo di produzione mediante l utilizzo come antigene di un isoforma della fad sintetasi umana |
EP2381958A1 (en) * | 2008-10-17 | 2011-11-02 | Tallinn University Of Technology | Potato virus a coat protein-based vaccine for treating melanoma and its use |
CA2740557C (en) | 2008-10-17 | 2020-04-14 | London Health Sciences Centre Research Inc. | Annexin and its use to treat inflammatory disorders |
EP2380023A2 (en) * | 2008-12-19 | 2011-10-26 | Medirista Biotechnologies AB | Oxidized cardiolipin as a novel pro-inflammatory factor |
CA2764029C (en) * | 2009-06-03 | 2019-10-29 | Mosamedix B.V. | Method for enhancing phagocytosis of phosphatidylserine-exposing cells |
CA2779577A1 (en) * | 2009-11-02 | 2011-05-05 | Therapeomic Ag | Stabilized protein formulations and use thereof |
CN103025757A (zh) * | 2010-04-29 | 2013-04-03 | 巴克斯特国际有限公司 | 二价阳离子结合蛋白在阴离子交换树脂上的纯化方法 |
ES2674567T3 (es) * | 2010-05-21 | 2018-07-02 | Merrimack Pharmaceuticals, Inc. | Proteínas de fusión biespecíficas |
CN102690345B (zh) | 2011-03-24 | 2014-03-19 | 江苏靶标生物医药研究所有限公司 | 人膜联蛋白v变体及其表达、制备和应用 |
DK2694538T3 (da) * | 2011-04-05 | 2017-01-02 | Annexin Pharmaceuticals Ab | Terapeutiske og profylaktiske fremgangsmåder, anvendelser og sammensætninger omfattende anexin a5 |
WO2013053888A1 (en) * | 2011-10-14 | 2013-04-18 | Baxter International Inc. | Protein purification by anion exchange chromatography |
WO2013170272A2 (en) | 2012-05-11 | 2013-11-14 | Alexander Krantz | Site-specific labeling and targeted delivery of proteins for the treatment of cancer |
AU2013340449B2 (en) * | 2012-11-05 | 2017-11-30 | Pfizer Inc. | Spliceostatin analogs |
DK2934582T3 (da) * | 2012-12-21 | 2020-02-24 | Ichnos Sciences SA | Anti-her2-antistofformulering |
WO2016115431A1 (en) * | 2015-01-16 | 2016-07-21 | The Johns Hopkins University | Methods for enhancing antigen-specific immune responses |
-
2015
- 2015-09-17 GB GB1516516.0A patent/GB2542391A/en not_active Withdrawn
-
2016
- 2016-09-16 CA CA3036298A patent/CA3036298A1/en active Pending
- 2016-09-16 ES ES18182321T patent/ES2920156T3/es active Active
- 2016-09-16 DK DK18182321.2T patent/DK3453721T3/da active
- 2016-09-16 JP JP2018514789A patent/JP6689371B2/ja active Active
- 2016-09-16 PL PL16766559T patent/PL3283506T3/pl unknown
- 2016-09-16 EP EP16766559.5A patent/EP3283506B1/en active Active
- 2016-09-16 CN CN201680053679.8A patent/CN108137662B/zh active Active
- 2016-09-16 ES ES16766559T patent/ES2699155T3/es active Active
- 2016-09-16 US US15/760,641 patent/US11773134B2/en active Active
- 2016-09-16 EP EP18182321.2A patent/EP3453721B1/en active Active
- 2016-09-16 CN CN202211002554.6A patent/CN116333087A/zh active Pending
- 2016-09-16 CA CA3193026A patent/CA3193026A1/en active Pending
- 2016-09-16 PL PL18182321.2T patent/PL3453721T3/pl unknown
- 2016-09-16 DK DK16766559.5T patent/DK3283506T3/en active
- 2016-09-16 WO PCT/EP2016/072066 patent/WO2017046391A2/en active Application Filing
- 2016-09-16 CN CN202211002553.1A patent/CN116333031A/zh active Pending
- 2016-09-16 EP EP22166813.0A patent/EP4134376A1/en active Pending
-
2018
- 2018-06-07 HK HK18107461.5A patent/HK1251580B/zh unknown
-
2019
- 2019-10-23 JP JP2019192805A patent/JP6910408B2/ja active Active
-
2021
- 2021-05-27 US US17/332,968 patent/US11472837B2/en active Active
- 2021-07-06 JP JP2021112221A patent/JP2021176856A/ja active Pending
-
2023
- 2023-03-17 JP JP2023042508A patent/JP2023088961A/ja active Pending
- 2023-08-04 US US18/365,712 patent/US20240116982A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL257411A (en) | Improved production of immunoglobulins | |
HK1251580B (zh) | 製造膜聯蛋白v的方法 | |
GB201517879D0 (en) | Method of deposition | |
ZA201706795B (en) | Process for the preparation of dicycloplatin | |
IL274142A (en) | A process for the preparation of sanicriviroc and related analogs | |
GB2522719B (en) | Method of manufacture | |
IL248267B (en) | A process for preparing converted cycloserines | |
IL252712A0 (en) | Method for protein production | |
GB201609170D0 (en) | Method of manufacture | |
PL3174402T3 (pl) | Proces produkcji proszku mlecznego | |
GB2522716B (en) | Method of manufacture | |
GB201613971D0 (en) | Method of manufacture | |
GB201609171D0 (en) | Method of manufacture | |
GB201601249D0 (en) | Production of manool | |
PL3271325T3 (pl) | Sposób wytwarzania (S)-metolachloru | |
GB2531092B (en) | Production of airframe components | |
GB201700973D0 (en) | Process of manufacture | |
IL247443B (en) | Process for the preparation of 5-fluorotryptophol | |
IL263300A (en) | METHODS FOR THE PRODUCTION OF CERTAIN CONVERSIONED SULPLAYIMINS | |
GB201700978D0 (en) | Process of manufacture | |
GB201602758D0 (en) | Method of manufacture | |
GB201600334D0 (en) | Method of manufacture | |
GB201600282D0 (en) | Method of manufacture | |
PT3271325T (pt) | Processo de produção de (s)-metolacloro | |
GB201417601D0 (en) | Articles of manufacture |